Clinical Trials
Sacituzumab Tirumotecan Safety Profile in Metastatic Triple-Negative Breast Cancer
Fan et alBreast Cancer Research

In a post-hoc exploratory safety analysis of the randomized OptiTROP-Breast01 trial (NCT05347134), investigators characterized the adverse event profile of sacituzumab tirumotecan (sac-TMT), a novel anti-trophoblast cell-surface antigen 2 (TROP-2) antibody-drug conjugate approved in China for second-line and subsequent treatment of metastatic triple-negative breast cancer (TNBC).
The safety analysis included 262 patients who received at least one dose of therapy: 130 patients assigned to sac-TMT and 132 assigned to treatment of physician’s choice (TPC). The evaluation placed particular emphasis on key adverse events (AEs), defined as stomatitis and hematologic toxicities, including anemia, neutropenia, and thrombocytopenia.
The median time to the onset of grade 3 or higher key adverse events primarily occurred within the first two cycles of sac-TMT therapy. Most patients experiencing these key AEs subsequently recovered to grade 2 or lower, typically within 14 days.
Subgroup analyses demonstrated that sac-TMT efficacy was generally comparable among patients with early dose reduction (within 2 months of treatment initiation), late dose reduction (after 2 months), or no dose reduction. Additionally, in patients with extended treatment durations exceeding 7 months, the incidence of both all-grade and grade 3 or higher treatment-related adverse events decreased over time, indicating that toxicities are manageable with appropriate supportive care and dose modifications without sacrificing therapeutic efficacy.
Key Takeaways
- Grade 3 or higher key adverse events—specifically stomatitis and hematologic toxicities (anemia, neutropenia, and thrombocytopenia)—primarily emerged within the first two cycles, with most sacituzumab tirumotecan-treated patients recovering to grade 2 or lower typically within 14 days.
- Clinical efficacy of sacituzumab tirumotecan was comparable across patient subgroups irrespective of whether dose reduction occurred early (within 2 months), late (after 2 months), or not at all.
- In patients receiving treatment for more than 7 months, the incidence of both any-grade and grade 3 or higher treatment-related adverse events decreased over time.
Read the original sourceBreast Cancer Research
